[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global canc-er statistics 2018:GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries[J]. CACancer J Clin, 2018, 68 (6) :394-424.
|
[2] SOBIN LH, COMPTON CC. TNM seventh edition:What's new, what's changed:Communication from the International Union A-gainst Cancer and the American Joint Committee on Cancer[J].Cancer, 2010, 116 (22) :5336-5339.
|
[3] OKUDA K, OHTSUKI T, OBATA H, et al. Natural history ofhepatocellular carcinoma and prognosis in relation to treat-ment. Study of 850 patients[J]. Cancer, 1985, 56 (4) :918-928.
|
[4] LLOVET JM, BRU C, BRUIX J. Prognosis of hepatocellularcarcinoma:The BCLC staging classification[J]. Semin LiverDis, 1999, 19 (3) :329-338.
|
[5] KUDO M, CHUNG H, HAJI S, et al. Validation of a new prog-nostic staging system for hepatocellular carcinoma:The JISscore compared with the CLIP score[J]. Hepatology, 2004, 40 (6) :1396-1405.
|
[6] LLOVET JM, BRUIX J. Prospective validation of the Cancer ofthe Liver Italian Program (CLIP) score:A new prognostic sys-tem for patients with cirrhosis and hepatocellular carcinoma[J]. Hepatology, 2000, 32 (3) :679-680.
|
[7] Committee of Liver Cancer of Chinese Anti-Cancer A. Clini-cal diagnosis and staging criteria for primary liver cancer[J].J Hepatol, 2001, 9 (6) :324.中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志, 2001, 9 (6) :324.
|
[8] YAU T, TANG VY, YAO TJ, et al. Development of Hong KongLiver Cancer staging system with treatment stratification for pa-tients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146 (7) :1691-1700. e1693.
|
[9] GUGLIELMI A, RUZZENENTE A, PACHERA S, et al. Compar-ison of seven staging systems in cirrhotic patients with hepato-cellular carcinoma in a cohort of patients who underwent radio-frequency ablation with complete response[J]. Am J Gastro-enterol, 2008, 103 (3) :597-604.
|
[10] Ministry of Health of the People’s Republic of China. Diagno-sis, management, and treatment of hepatocellular carcinoma (V2011) [J]. J Clin Hepatol, 2011, 27 (11) :1141-1159.中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1159.
|
[11] BRUIX J, REIG M, SHERMAN M. Evidence-based diagno-sis, staging, and treatment of patients with hepatocellular car-cinoma[J]. Gastroenterology, 2016, 150:835-853.
|
[12] CHU KK, CHEUNG TT. Update in management of hepatocel-lular carcinoma in Eastern population[J]. World J Hepatol, 2015, 7 (11) :1562-1571.
|
[13] TORZILLI G, DONADON M, MARCONI M, et al. Hepatecto-my for stage B and stage C hepatocellular carcinoma in theBarcelona Clinic Liver Cancer classification:Results of a pro-spective analysis[J]. Arch Surg, 2008, 143 (11) :1082-1090.
|
[14] CHEN XP, HUANG ZY. Surgical treatment of hepatocellularcarcinoma in China:Surgical techniques, indications, andoutcomes[J]. Langenbecks Arch Surg, 2005, 390 (3) :259-265.
|
[15] VITALE A, SARACINO E, BOCCAGNI P, et al. Validation ofthe BCLC prognostic system in surgical hepatocellular cancerpatients[J]. Transplant Proc, 2009, 41 (4) :1260-1263.
|
[16] YAN X, FU X, CAI C, et al. Validation of models in patientswithhepatocellular carcinoma:Comparison of Hong Kong LiverCancer with Barcelona Clinic Liver Cancer staging system in aChinese cohort[J]. Eur J Gastroenterol Hepatol, 2015, 27 (10) :1180-1186.
|
[17] YAU T, TANG VY, YAO TJ, et al. Development of Hong KongLiver Cancer Staging System with treatment stratification forpatients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146 (7) :1691-1700.
|
[18] LIU PH, HSU CY, LEE YH, et al. Hong Kong Liver CancerStaging System is associated with better performance for hep-atocellular carcinoma:Special emphasis on viral etiology[J].Medicine (Baltimore) , 2015, 94 (41) :e1772.
|
[19] LEE YS, SEO YS, KIM JH, et al. Can more aggressive treat-ment improve prognosis in patients with hepatocellular carcino-ma? A direct comparison of the Hong Kong liver cancer andBarcelona clinic liver cancer algorithms[J]. Gut liver, 2018, 12 (1) :94-101.
|
[20] ADHOUTE X, PENARANDA G, BRONOWICKI JP, et al. Use-fulness of the HKLC vs. the BCLC staging system in a Europe-an HCC cohort[J]. J Hepatol, 2015, 62 (2) :492-493.
|
[21] KOLLY P, REEVES H, SANGRO B, et al. Assessment of theHong Kong Liver Cancer staging system in Europe[J]. LiverInt, 2016, 36 (6) :911-917.
|